Despite a post-settlement price drop, dark pool data reveals aggressive institutional accumulation in Arbutus Biopharma, not selling.

Rocket Lab's stock fell 30% after a planned insider sell-off. The distribution phase is now over, signaling a potential stealth re-accumulation by smart money.

Novavax is undervalued. It holds $751M cash, has profitable licensing deals for its Matrix-M tech, and faces activist pressure to unlock shareholder value. The market ignores this shift.

OKUR's stock trades at a negative enterprise value after a $150M private placement. Investors buy the company's IP and cash for less than the cash itself, a deep-value anomaly.

CAI stock is down 50% despite 97% revenue growth. The plunge is a market illusion, with dark pool data showing heavy institutional accumulation, not a fundamental failure.

Zai Lab (ZLAB) crashed to $16.30 in early 2026 due to forced institutional selling. However, sharp hedge fund RA Capital bought a 5.2% stake at the bottom, signaling a major accumulation event hidden in dark pool data.

Alumis's stock surge is a cynical liquidity event. Insiders bought low, hyped Phase 3 data, then sold shares high in a $345M offering. Despite cash, the drug faces a crowded market and massive cash burn.

LUNR is a mispriced, gov-backed space infrastructure play. Its revenue is set to quintuple in 2026. High short interest and a tiny, locked-up float create a massive squeeze potential.

Robinhood stock crashed 55% despite strong fundamentals, as insiders sold millions of shares at peak prices. Now, extreme off-exchange trading signals suggest major institutional accumulation at the $68 level.

Centene's $6.7B non-cash impairment triggered a sell-off, but the firm has $17B cash. Sophisticated funds are buying as insiders align for a major stock price recovery.

Target Hospitality (TH) pivots from oil to AI infrastructure, securing a $550M+ contract to house data center workers, driving a major stock surge.

Vor Biopharma executed a reverse split, insider selling, and major capital raises. This crushed the stock price but secured $450M cash, resetting the company for institutional investors.

Lululemon's stock is down 44% despite strong cash flow & 60% margins. The market overreacted to a US slowdown, ignoring international growth & a $1B buyback. Activist pressure from founder Chip Wilson could unlock value.

Ciena's stock soared 500% on AI hype, but its 440x P/E ratio and exhausted short squeeze signal a dangerous bubble primed for a sharp correction.

Cheesecake Factory's revenue growth masks a 2.2% same-store sales decline. It's funding dividends and buybacks with new debt while insiders sell, signaling deep financial trouble.

Aeluma's high short interest is a trap. The company has a strong cash position, and recent insider selling represents a cap table rotation, not a failing business. Bears are misreading the data.

Cogent Biosciences' stock surged nearly 500% on strong drug trial data. However, insiders are selling, a large convertible note offering creates a price ceiling, and the stock now prices in perfection, suggesting the rally may be over.

Smart money orchestrated a VOR Biopharma sell-off, then bought back shares at a 60% discount via a PIPE, recapitalizing the company. Retail was washed out.

Wave Life Sciences' stock crashed 50% on obesity drug data. But the drug targets toxic fat & preserves muscle, unlike GLP-1s. Insiders are buying, seeing a misunderstood RNA editing pioneer, not a failure.

Halozyme's stock drop is misunderstood. The "institutional selling" is an accounting change, not a real exit. Insider sales are pre-planned for taxes. The CEO's new pay package requires the stock to hit $115 to fully vest, showing strong board confidence.